The increase in price target from $7 to $15 by RBC Capital indicates a significant positive reassessment of WAVE Life Sciences' potential. Maintaining a Sector Perform rating suggests that while the stock is expected to perform well, it may not outperform the sector. The substantial increase in the price target is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.